Akums Drugs and Pharmaceuticals has secured approval from Drugs Controller General of India for its ground-breaking triple combination diabetes treatment. Sitagliptin 100, pioglitazone 15 and metformin 1000/500 comes as a more advanced treatment for diabetes, with much more efficacy and precision than monotherapy drugs that are currently in the market.
Sitagliptin 100, pioglitazone 15 and metformin 1000/500 is specifically formulated for the treatment of diabetes and offers a number of pharmacological advantages.
The combination contains three distinctly active formulations such as metformin, a glucose-lowering agent often prescribed as a first-line therapy for type-2 diabetes (T2D).
"We have carefully studied the pharmacological properties of these formulations and with sitagliptin 100, pioglitazone 15 and metformin 1000/500, we found the right blend for our triple-active combination. This is going to better serve anti-diabetic patients who require better treatment without necessarily swallowing multiple drugs. The approval is a boost because it shows that we followed all laid down procedures, and the drug is fit for use by patients who need relief from the impacts of not just type-2 diabetes, Patient convenience and dosage compliance " said Sanjeev Jain, joint managing director, Akums Drugs & Pharmaceuticals.
The bi-layered combination was formulated following well-researched processes and operations, as well as adherence to pharmacological guidelines. Speaking on the approval, Sandeep Jain, jt. managing director, Akums Drugs & Pharmaceuticals, noted that the renoprotective effects of drugs like metformin coupled with the functional and corrective influence of pioglitazone on beta-cell and metabolic syndrome, and the stability of sitagliptin, make an effective solution for diabetes.
